AGIOS PHARMACEUTICALS, INC. Income Tax Examination, Penalties and Interest Expense
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Income Tax Examination, Penalties and Interest Expense of $0 for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-24.
Discontinued › Expense Statement
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2016-11-03
- AGIOS PHARMACEUTICALS, INC. income tax examination, penalties and interest expense for the quarter ending 2013-12-31 was $190.00K, a 17.39% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. income tax examination, penalties and interest expense for the quarter ending 2013-09-30 was $121.00K, a 27.98% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. income tax examination, penalties and interest expense for the quarter ending 2013-06-30 was $99.00K, a 39.63% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. income tax examination, penalties and interest expense for the quarter ending 2012-12-31 was $230.00K.
- AGIOS PHARMACEUTICALS, INC. income tax examination, penalties and interest expense for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- AGIOS PHARMACEUTICALS, INC. income tax examination, penalties and interest expense for fiscal 2013 was $600.00K, a 0.00% change from fiscal 2012.
- AGIOS PHARMACEUTICALS, INC. income tax examination, penalties and interest expense for fiscal 2012 was $600.00K, a 100.00% increase from fiscal 2011.
- AGIOS PHARMACEUTICALS, INC. income tax examination, penalties and interest expense for fiscal 2011 was $300.00K.
| Period end | Income Tax Examination, Penalties and Interest Expense 1 month | Income Tax Examination, Penalties and Interest Expense 3 month | Income Tax Examination, Penalties and Interest Expense 6 month | Income Tax Examination, Penalties and Interest Expense 9 month | Income Tax Examination, Penalties and Interest Expense 12 month |
|---|---|---|---|---|---|
| 2014-12-31 | $0.00 10-K · filed 2015-02-24 | ||||
| 2014-01-31 | $1.50M 10-Q · filed 2016-11-03 | ||||
| 2013-12-31 | $190.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $311.00K derived: sum of 2 quarters · filed 2015-02-24 | $410.00K derived: sum of 3 quarters · filed 2015-02-24 | $600.00K 10-K · filed 2015-02-24 | |
| 2013-09-30 | $121.00K 10-Q · filed 2013-11-07 | $220.00K derived: sum of 2 quarters · filed 2013-11-07 | $410.00K 10-Q · filed 2013-11-07 | ||
| 2013-06-30 | $99.00K 10-Q · filed 2013-09-05 | $289.00K 10-Q · filed 2013-09-05 | |||
| 2012-12-31 | $230.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $398.00K derived: sum of 2 quarters · filed 2015-02-24 | $562.00K derived: sum of 3 quarters · filed 2015-02-24 | $600.00K 10-K · filed 2015-02-24 | |
| 2012-09-30 | $168.00K 10-Q · filed 2013-11-07 | $332.00K derived: sum of 2 quarters · filed 2013-11-07 | $370.00K 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | $164.00K 10-Q · filed 2013-09-05 | $202.00K 10-Q · filed 2013-09-05 | |||
| 2011-12-31 | $300.00K 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |